FDA authorized Quest Diagnostics COVID-19 diagnostic testing for specimen pooling for emergency use

On Jul. 18, 2020, a Health Trendsル study from researchers at Quest Diagnostics and the University of Pittsburgh Medical Center provided new evidence that the HPV screening test is significantly less likely to detect cervical cancer and precancer than cotesting, a method which combines HPV and Pap (Papanicolaou test by liquid based cytology) testing using the same specimen.

Tags:


Source: Quest Diagnostics
Credit: